Netherlands· NL-3efa6a35fd65

Cardioxane 500 mg poeder voor oplossing voor infusie

A dexrazoxane product containing dexrazoxaan hydrochloride, registered in Netherlands by CNX Therapeutics Ireland Limited. The same ATC class is registered in 15 of our 19 countries.

ATC V03AF02

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about dexrazoxaan hydrochlorideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Dexrazoxane is registered in 15 of 19 countries.

Countries holding a registration under ATC V03AF02 (dexrazoxane), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search dexrazoxane products by name

Dexrazoxane · ATC V03AF02

15 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Japan
Netherlands
Norwayprice
Polandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of dexrazoxane costs, country by country.

Normalised to the WHO defined daily dose (1.5 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Dexrazoxane · price per daily dose (1.5 g)

USD · FX 28 Sept 2026

FI Finland$8.88

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: DEXRAZOXAAN HYDROCHLORIDE
Manufacturer: CNX Therapeutics Ireland Limited
Country: Netherlands (NL)
ATC code: V03AF02
ATC class: Dexrazoxane
Defined daily dose: 1.5 g, P
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
33196

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

8 interactions on record for dexrazoxane.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check dexrazoxane against other medicines How interaction checks work

Dexrazoxane · interactions on record

8 records

2 severe
6 moderate

Most severe, free to view

Talimogene laherparepvecL01XL02severe
Talimogen laherparepvecL01XX51severe
Lactobacillus acidophilusJ07AX04moderate
DoxorubicinL01DB01moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dexrazoxane in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dexrazoxane products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

Austria · Cyrdanax
Czechia · Cyrdanax
Germany · Cardioxane, Cyrdanax
Spain · Cardioxane
France · Cardioxane, Cyrdanax
United Kingdom (Northern Ireland) · Cardioxane
Hungary · Cyrdanax
Iceland · Savene
Italy · Cardioxane
Liechtenstein · Savene
Norway · Savene
Poland · Cyrdanax
Romania · Cyrdanax
Slovakia · Cyrdanax

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/cfa528a2-28a5-440e-bdf1-ad1c5d005464
GET /v1/drugs/cfa528a2-28a5-440e-bdf1-ad1c5d005464?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h33196_smpc.pdf",
  "strength": null,
  "atc_label": "Dexrazoxane",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg33196",
  "excipients": [
    "STIKSTOF (HEAD SPACE) (E 941)"
  ],
  "substances": [
    "DEXRAZOXAAN HYDROCHLORIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h33196.pdf",
  "authorised_at": "2006/12/05",
  "procedure_number": "FR/H/0283/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "33196",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about dexrazoxane.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console